Boston Scientific Corporation $BSX Shares Acquired by NBT Bank N A NY

NBT Bank N A NY increased its stake in Boston Scientific Corporation (NYSE:BSX) by 4.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,842 shares of the medical equipment provider’s stock after acquiring an additional 153 shares during the period. NBT Bank N A NY’s holdings in Boston Scientific were worth $413,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of BSX. Vanguard Group Inc. boosted its position in shares of Boston Scientific by 1.3% in the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock worth $13,577,311,000 after acquiring an additional 1,697,945 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Boston Scientific by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock worth $1,070,387,000 after acquiring an additional 1,664,108 shares during the last quarter. Swedbank AB raised its holdings in Boston Scientific by 114.5% in the second quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock valued at $302,816,000 after buying an additional 1,505,019 shares during the period. Goldman Sachs Group Inc. raised its holdings in Boston Scientific by 10.8% in the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after buying an additional 1,383,524 shares during the period. Finally, Ninety One UK Ltd raised its holdings in Boston Scientific by 33.5% in the second quarter. Ninety One UK Ltd now owns 5,146,218 shares of the medical equipment provider’s stock valued at $552,755,000 after buying an additional 1,290,414 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Leerink Partners raised their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Royal Bank Of Canada restated an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a report on Monday, September 29th. Raymond James Financial raised their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a report on Thursday, July 24th. Evercore ISI cut their price target on shares of Boston Scientific from $115.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, Canaccord Genuity Group lifted their price objective on shares of Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a research note on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $120.71.

Boston Scientific Stock Up 0.5%

Shares of NYSE:BSX opened at $97.28 on Friday. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The company has a fifty day simple moving average of $102.18 and a 200 day simple moving average of $101.92. The firm has a market cap of $144.14 billion, a PE ratio of 57.91, a price-to-earnings-growth ratio of 2.33 and a beta of 0.61. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business’s revenue was up 22.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. This represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $17,972,457 in the last ninety days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.